JAZZJazz PharmaceuticalsFinished
A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer
HER2-expressing Cancers
12Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Aug 2025, none posted yet
Counts until it's fixed
- +1.5
3 insiders sold shares within a month
Since May 28, 2026 · was worth 10, fading over time
Worry score12
Score over time
- Stage
- Phase 1/2
- Patients
- 52 (final count)
- Started
- Sep 15, 2021
- Main results expected
- Aug 29, 2025
- Fully finished
- Sep 30, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of dose-limiting toxicities (DLTs; Part 1)
Measured over: Up to 4 weeks
Incidence of AEs (Part 1)
Measured over: Up to 7 months
Incidence of clinical laboratory abnormalities (Part 1)
Measured over: Up to 7 months
Confirmed objective response rate (ORR)(Part 2)
Measured over: Up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-08-29, no fading
- insider_selling_cluster: base 10, now 1.5, since 2026-05-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05027139 · record last updated 2026-07-01 · checked 2026-11-09 15:47 UTC